Genentech Seeking to Expand Tarceva into First-Line Setting in EGFR-Mutated NSCLC Patients | GenomeWeb

Originally published June 6.

By Turna Ray

CHICAGO — Roche subsidiary Genentech is in discussions with the US Food and Drug Administration about launching the non-small cell lung cancer drug Tarceva as a first-line treatment for patients with EGFR-mutated tumors. If Tarceva is launched in this indication, it will serve as an example of the use of a pharmacogenomics strategy to successfully grow a drug's market size.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Researchers link obesity in Labrador retrievers to a deletion in their POMC gene.

In Cell this week: transcriptional map of human embryo development, circadian clock genes in acute myeloid leukemia, and more.

The US National Academy of Sciences has announced 84 new members and 21 foreign associates.

The users of file-sharing site Sci-Hub work all around the globe where research is going on, Science's John Bohannon reports.